Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
YagamiNGO:7488 -0.40%69 Equity-to-Asset is 0.77 as of Apr. 2026, which is 7% above its 10-year median of 0.72. GuruFocus rates NGO:7488 with a GF Score™ of 69/100 and a GF Value™ of 円3,110.20 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 124 Medical Distribution companies, Yagami ranks better than 93.55% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Yagami's Total Stockholders Equity for the quarter that ended in Apr. 2026 was 円13,924 Mil. Yagami's Total Assets for the quarter that ended in Apr. 2026 was 円18,077 Mil.
The historical rank and industry rank for Yagami's Equity-to-Asset or its related term are showing as below:
NGO:7488'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.7 Med: 0.72 Max: 0.78
Current: 0.78
During the past 13 years, the highest Equity to Asset Ratio of Yagami was 0.78. The lowest was 0.70. And the median was 0.72.
NGO:7488's Equity-to-Asset is ranked better than 93.55% of 124
companies
in the Medical Distribution industry
Industry Median: 0.395
vs NGO:7488: 0.78
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Yagami Equity-to-Asset Related Terms
Yagami Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Yagami's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGO:7488 vs MCK, COR, CAH: Equity-to-Asset Comparison
For the Medical Distribution subindustry, Yagami's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yagami Equity-to-Asset vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Yagami's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Yagami's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Yagami's Equity to Asset Ratio for the fiscal year that ended in Apr. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yagami (NGO:7488) has a Equity-to-Asset of 0.77 as of Apr. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Yagami and its competitors. This is near median its historical median of 0.72. Over the past decade, Yagami's Equity-to-Asset has ranged from 0.70 to 0.78. According to the industry distribution chart, Yagami ranks #8 out of 124 companies in the Medical Distribution industry, placing it in the top 6.5%.
Is Yagami's Equity-to-Asset too high?
Yagami's current Equity-to-Asset of 0.77 is near median its 10-year median of 0.72. Over the past 10 years, this metric has ranged from a low of 0.70 to a high of 0.78. The Medical Distribution industry median Equity-to-Asset is 0.40. Yagami's value of 0.77 is 94.9% above this industry median. Based on the distribution chart, Yagami ranks #8 out of 124 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Yagami has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Yagami's Equity-to-Asset compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Yagami ranks #8 out of 124 companies for Equity-to-Asset. This places Yagami in the top 7% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.40. Yagami's value of 0.77 is 94.9% above this benchmark. Historically, Yagami's own Equity-to-Asset has ranged from 0.70 to 0.78 over the past decade. While the company's 10-year median is 0.72 vs. the industry median of 0.40, Yagami has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Distribution company?
The median Equity-to-Asset among Medical Distribution companies is 0.40, based on 124 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yagami's current Equity-to-Asset of 0.77 is 94.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Yagami and its competitors. For the Medical Distribution industry, the median Equity-to-Asset is 0.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yagami's current Equity-to-Asset is 0.77, which is near median its own 10-year median of 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yagami stock overvalued right now?
Based on GuruFocus' analysis, Yagami (NGO:7488) is currently considered Significantly Overvalued. The stock's GF Value™ is 円3,110.20, compared to a current price of 円4,970.00 — trading 59.8% above its estimated fair value. The current Equity-to-Asset is 0.77, which is near median its 10-year median of 0.72 and 94.9% above the Medical Distribution industry median of 0.40. Yagami's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Yagami (NGO:7488), the current Equity-to-Asset is 0.77 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Yagami (NGO:7488) Overvalued in 2026?
Based on GuruFocus' analysis, Yagami stock appears to be overvalued.
The current stock price of 円4,970.00 is trading 59.8% above its estimated GF Value™ of 円3,110.20.
GuruFocus considers Yagami to be Significantly Overvalued.
Key valuation signals for NGO:7488:
Equity-to-Asset: 0.77 (near median its 10-year median of 0.72)
GF Value™: 円3,110.20 vs. price of 円4,970.00 (59.8% above fair value)
Industry Position: 94.9% above the Medical Distribution median (#8 of 124)
No single metric tells the full story. See the NGO:7488 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Yagami Inc is a Japan based company engaged in providing science education equipment, laboratory tables, kitchen tables, sterilizers, nurse's office equipment, AEDs (automated external defibrillators), human body models for resuscitation education, electric heaters for keeping warm and heating, and environmental testing equipment.
69GF Score
Get the complete analysis for NGO:7488
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGO:7488 has been successfully added to your 
